Bernard Bégaud
Bernard Bégaud
Verified email at
Cited by
Cited by
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
L Abenhaim, Y Moride, F Brenot, S Rich, J Benichou, X Kurz, ...
New England Journal of Medicine 335 (9), 609-616, 1996
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study
E Bruckert, G Hayem, S Dejager, C Yau, B Bégaud
Cardiovascular drugs and therapy 19 (6), 403-414, 2005
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
S Picard, K Titier, G Etienne, E Teilhet, D Ducint, MA Bernard, R Lassalle, ...
Blood 109 (8), 3496-3499, 2007
Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France
B Bégaud, JC Evreux, J Jouglard, G Lagier
Thérapie (Paris) 40 (2), 111-118, 1985
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study
P Pouyanne, F Haramburu, JL Imbs, B Bégaud
Bmj 320 (7241), 1036, 2000
Use of oral corticosteroids in the United Kingdom
TP Van Staa, HGM Leufkens, L Abenhaim, B Begaud, B Zhang, C Cooper
Qjm 93 (2), 105-111, 2000
Benzodiazepine use and risk of Alzheimer’s disease: case-control study
SB De Gage, Y Moride, T Ducruet, T Kurth, H Verdoux, M Tournier, ...
Bmj 349, g5205, 2014
Benzodiazepine use and risk of dementia: prospective population based study
SB de Gage, B Bégaud, F Bazin, H Verdoux, JF Dartigues, K Pérès, ...
Bmj 345, 2012
Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France
B Begaud, JC Evreux, J Jouglard, G Lagier
Therapie 40 (2), 111, 1985
Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system
A Alvarez-Requejo, A Carvajal, B Begaud, Y Moride, T Vega, LHM Arias
European journal of clinical pharmacology 54 (6), 483-488, 1998
Under‐reporting of adverse drug reactions in general practice
Y Moride, F Haramburu, AA Requejo, B Begaud
British journal of clinical pharmacology 43 (2), 177-181, 1997
Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies
H Verdoux, M Tournier, B Begaud
Acta Psychiatrica Scandinavica 121 (1), 4-10, 2010
Adverse drug reaction monitoring: doing it the French way
N Moore, G Paux, B Begaud, M Biour, E Loupi, F Boismare, RJ Royer
The Lancet 326 (8463), 1056-1058, 1985
Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability
R Lagnaoui, N Moore, J Fach, M Longy-Boursier, B Begaud
European journal of clinical pharmacology 56 (2), 181-186, 2000
Benzodiazepine use in an elderly community-dwelling population
A Fourrier, L Letenneur, J Dartigues, N Moore, B Bégaud
European journal of clinical pharmacology 57 (5), 419-425, 2001
Patterns and correlates of benzodiazepine use in the French general population
R Lagnaoui, F Depont, A Fourrier, A Abouelfath, B Begaud, H Verdoux, ...
European journal of clinical pharmacology 60 (7), 523-529, 2004
Rates of spontaneous reporting of adverse drug reactions in France
B Bégaud, K Martin, F Haramburu, N Moore
Jama 288 (13), 1588-1588, 2002
Differences between clinical trials and postmarketing use
K Martin, B Bégaud, P Latry, G Miremont‐Salamé, A Fourrier, N Moore
British journal of clinical pharmacology 57 (1), 86-92, 2004
Benzodiazepine use and risk of dementia: a nested case–control study
R Lagnaoui, B Bégaud, N Moore, A Chaslerie, A Fourrier, L Letenneur, ...
Journal of clinical epidemiology 55 (3), 314-318, 2002
Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non‐case study in the French pharmacovigilance system database
N Moore, C Kreft‐Jais, F Haramburu, C Noblet, M Andrejak, M Ollagnier, ...
British journal of clinical pharmacology 44 (5), 513-518, 1997
The system can't perform the operation now. Try again later.
Articles 1–20